Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Cyclopharm Limited ( (AU:CYC) ) is now available.
Cyclopharm Limited has confirmed that its insurer has accepted indemnity for legal proceedings brought against the company by 4DMedical Limited in the Supreme Court of Victoria and has taken over conduct of Cyclopharm’s defence. The insurer’s assumption of the defence is expected to mitigate potential financial and operational impacts on Cyclopharm as the case progresses, providing greater certainty for investors and other stakeholders while the company continues its focus on its core radiopharmaceutical operations and ongoing disclosure obligations.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.88 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company serving the global medical community. Its core product, Technegas, is used for functional lung ventilation imaging, historically in the diagnosis of pulmonary embolism and increasingly in other respiratory and interventional indications such as COPD, asthma, pulmonary hypertension, and lung cancer-related surgeries.
Average Trading Volume: 62,635
Technical Sentiment Signal: Sell
Current Market Cap: A$97.8M
For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.